EW vs DXCM — Key Metrics
| Metric | EW (EDWARDS LIFESCIENCES CORP) | DXCM (DEXCOM INC) |
|---|---|---|
| Price | 105.23 | 82.52 |
| Market Cap | 60.51 Billion | 30.78 Billion |
| P/E (TTM) | 59.45 | 31.86 |
| P/B (Quarterly) | 5.261 | 11.758 |
| P/S (TTM) | 9.07 | 6.03 |
| Net Profit Margin (TTM) | 15.3 | 19.4 |
| Gross Margin (TTM) | 78.0 | 63.4 |
| ROE (TTM) | 9.7 | 36.5 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Recommendation Summary
Stock EW is projected to underperform the market, stock DXCM is projected to outperform the market. Upfront Recommendation: DXCM.
Financial Metrics
| EW | Metrics | DXCM |
|---|---|---|
| $105.23 | Price | $82.52 |
| — | Market Capitalization | — |
| 59.45 | Price to Earnings Ratio | 31.86 |
| 9.07 | Price to Sales | 6.03 |
| 42.49 | Price to FCF Ratio | 28.02 |
| 11.62 | Price to Gross Profit | 9.51 |
| 55.45 | Price to R&D | 50.61 |
| 8.35 | Price to Current Assets | 7.86 |
EW vs DXCM at a glance
Edwards Lifesciences Corp (EW) and Dexcom INC (DXCM) are both Medical Devices companies in the Healthcare sector. EW is the larger, at $60.5 billion in market value against $30.8 billion for DXCM, about 2.0 times the size.
On trailing-twelve-month figures, EW trades at 59.5 times trailing earnings and DXCM at 31.9; net profit margins are 15.3% and 19.4%.
The Upfront Investment model currently rates EW Underperform and DXCM Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.